Evidence map›Paper›PMID 39630347›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2024

Multiorgan-on-a-chip for cancer drug pharmacokinetics-pharmacodynamics (PK-PD) modeling and simulations.

Abdurehman Eshete Mohammed, Filiz Kurucaovalı, Devrim Pesen Okvur

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Novel emerging cell and organoid systems for the study of drug metabolism and toxicity in humans.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Abdurehman Eshete MohammedDepartment of Molecular Biology and Genetics, Izmir Institute of Technology, Izmir, Turkey. abdurehman.eshete@wu.edu.et.ORCID 0000-0002-9459-8378
Filiz KurucaovalıEnvironmental Development Application and Research Center, Izmir Institute of Technology, Izmir, Turkey.
Devrim Pesen OkvurDepartment of Molecular Biology and Genetics, Izmir Institute of Technology, Izmir, Turkey.

Funding

Izmir Institute of Technology BAP project IYTE0277
6 · The paper itself

Abstract

Cancer is one of the most common and fatal diseases worldwide and kills millions of people every year. Cancer drug resistance, lack of efficacy, and safety are significant problems in cancer patients. A multiorgan-on-a-chip (MOC) device consisting of breast and liver compartments was designed with AutoCAD software. The MOC molds were printed by a Formlabs Form 2 3D printer. MDA-MB-231, HepG2, and MCF-10 A cells were used for the MOC experiments. The cell lines were cultured at 37 °C with 5% CO

Indexed as

Antineoplastic AgentsComputer SimulationModels, BiologicalCell Line, TumorCell SurvivalFemaleHep G2 CellsHumansLab-On-A-Chip DevicesLiverAntineoplastic AgentsBreast cancerEfficacyMultiorgan-on-a-chipPharmacodynamicsPharmacokineticsPharmacometricsSafety

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.